ASCO 2024 | Ascentage Pharma Releases Latest Results from Mu

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Related Keywords

Zhejiang , China , Hong Kong , United States , Hangzhou , Suzhou , Jiangsu , Chicago , Illinois , Guangzhou , Guangdong , Jilin , Rockville , Melbourne , Victoria , Australia , Chinese , American , Yuxiang Ma , Haibo Qiu , Masa Lasica , Prnewswire Ascentage Pharma , Huafeng Wang , Ascentage Pharma , Yifan Zhai , Md Anderson Cancer Center , American Society Of Clinical Oncology , Sun Yat Sen University Cancer Center , Zhejiang University School Of Medicine , Major National , Dana Farber Cancer Institute , China National Medical Products Administration , National Reimbursement Drug List , Astrazeneca , Clinical Oncology , Annual Meeting , Oral Reports , Chief Medical Officer , Central Time , Hematologic Malignancies , Myelodysplastic Syndromes , First Affiliated Hospital , Zhejiang University School , Chronic Lymphocytic , Developmental Therapeutics , Molecularly Targeted Agents , Main Board , Stock Exchange , Hong Kong Limited , Major National Rd Projects , Major New Drug Projects , New Drug Incubator , Innovative Drug Programs , Major Project , Priority Review Designations , Breakthrough Therapy Designations , Drug Evaluation , Reimbursement Drug List , Orphan Drug Designation , Fast Track Designation , Orphan Designation , Cancer Center , Mayo Clinic ,